USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE
本页收录老挝专利「USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE」的公开登记要点，由 SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 于 2016-05-12 提交申请，当前状态为已放弃。公开档案中可核验：申请号 P/599，DIP 编号 LAP599，主管局代码 LA，保护类型 Patent - PCT National Phase。时间线要点：公开/公告日 2026-01-16。国际分类 / IPC 标注为 A61K 31/7048、A61P 31/06。发明人 / 设计人包括 HE, Weiqing、JIANG, Yang、WANG, Yiguang、ZHAO, Xiaofeng。代理机构 / 代理人记载为 CONCETTI-LAO CO., LTD。公开摘要提示：Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in myco…。
This Laos patent “USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE” is a public DIP intellectual-property record, filed by SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 on 2016-05-12; current status: Abandoned. Identifiers include application No. P/599; DIP id LAP599; protection kind Patent - PCT National Phase. Key dates: publication 2026-01-16. Classification: A61K 31/7048、A61P 31/06. Inventor(s)/designer(s): HE, Weiqing, JIANG, Yang, WANG, Yiguang, ZHAO, Xiaofeng. Abstract hint: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in myco…. Unique application identifiers, holders and classification text are surfaced here to reduce near-duplicate IP landing pages; always verify against the competent office.
ກ່ຽວກັບ ສິດທິບັດ «USE OF CARRIPIYCIN IN MYCOBACTERIUM TUBERCULOSIS INFECTI0N RESISTANCE» ໃນລາວ, ຍື່ນໂດຍ SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。 ໃນວັນທີ 2016-05-12; ສະຖານະ ປະຖິ້ມ. ຕົວລະບຸ: ເລກທີຄຳຮ້ອງ P/599; ລະຫັດ DIP LAP599; ປະເພດການປົກປ້ອງ Patent - PCT National Phase. ວັນທີສຳຄັນ: ວັນເຜີຍແຜ່ 2026-01-16. ປະເພດ/ຫ້ອງ: A61K 31/7048、A61P 31/06. ນັກປະດິດ/ນັກອອກແບບ: HE, Weiqing, JIANG, Yang, WANG, Yiguang, ZHAO, Xiaofeng. ສະຫຼຸບ: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in myco…. ຂໍ້ຄວາມນີ້ເນັ້ນຕົວເລກ, ວັນທີ, ປະເພດ ແລະ ຜູ້ຍື່ນ ເພື່ອຫຼຸດຄວາມຄ້າຍຄືນລະຫວ່າງໜ້າ IP; ກວດຂໍ້ມູນທາງການກ່ອນຕັດສິນໃຈ.
P/599
图样
基础信息
- 类型
- 专利
- 申请号
P/599- 状态
- 已放弃
- 申请人
- SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO.,LTD。
- 代理机构
- CONCETTI-LAO CO., LTD
- 申请日期
- 2016-05-12
- 公开/公告日
- 2026-01-16
- 国际分类
- A61K 31/7048 · A61P 31/06
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查 进行中
-
实质审查
-
公开
-
授权
关联分析
LaoBiz 企业数据库联动类似专利推荐
摘要
Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.